Drug Overview
In the clinical specialty of Endocrinology, the management of Type 2 Diabetes has evolved toward “multi-pathway” pharmaceutical interventions that address both insulin resistance and glucose disposal. Invokamet-XR is a high-potency pharmaceutical intervention belonging to the SGLT2 / Biguanide Combo drug class. It is a fixed-dose, extended-release combination of canagliflozin (an SGLT2 inhibitor) and metformin hydrochloride (a biguanide).
As a Targeted Therapy, Invokamet-XR is utilized for the treatment of Type 2 Diabetes. By utilizing an extended-release (XR) delivery system, it provides a consistent concentration of metformin over a 24-hour period, which typically improves gastrointestinal tolerability compared to immediate-release formulations. This combination offers a synergistic approach: metformin reduces hepatic glucose production, while canagliflozin facilitates the renal excretion of glucose.
- Generic Name: Canagliflozin and Metformin HCl Extended-Release
- US Brand Names: Invokamet-XR
- Drug Class: SGLT2 Inhibitor / Biguanide Combination
- Drug Category: Endocrinology / Oral Antidiabetic Agents
- Route of Administration: Oral Tablet (Extended-Release)
- FDA Approval Status: FDA-approved (2016) for glycemic control and subsequent indications for cardiovascular and renal protection.
Invokamet-XR is an extended-release SGLT2/biguanide combo for optimal Type 2 Diabetes care. Explore advanced metabolic treatments at our hospital.
What Is It and How Does It Work? (Mechanism of Action)
Invokamet-XR functions through two distinct, complementary mechanisms of action that target different physiological drivers of hyperglycemia.
1. Metformin HCl (Extended-Release): The Sensitizer
Metformin acts primarily by activating AMP-activated protein kinase (AMPK).
- Hepatic Suppression: It inhibits gluconeogenesis, significantly reducing the amount of glucose the liver releases into the blood.
- Peripheral Sensitivity: It enhances insulin sensitivity in skeletal muscle, improving glucose uptake and utilization.
- Extended-Release Technology: The XR formulation uses a polymer matrix that slowly releases metformin as it passes through the digestive tract, minimizing the “spike” in concentration that often leads to nausea and diarrhea.
2. Canagliflozin: The Excretor
Canagliflozin targets the Sodium-Glucose Co-Transporter 2 (SGLT2) in the proximal convoluted tubule of the kidney.
- Blocking Reabsorption: Under normal conditions, the kidneys reabsorb ~90% of filtered glucose back into the blood. Canagliflozin blocks this transporter.
- Glucosuria: Excess glucose is physically eliminated from the body via the urine. This mechanism is entirely independent of insulin, making it effective even as pancreatic beta-cell function declines.
Synergistic Result
By combining these two, Invokamet-XR addresses the “Ominous Octet” of diabetes pathophysiology, specifically liver overproduction and renal reabsorption, while also facilitating a modest caloric loss (roughly 200–300 calories/day) through excreted sugar.
FDA-Approved Clinical Indications
Primary Indication
The primary indication for Invokamet-XR is as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 Diabetes.
Cardiorenal and Protective Indications
Due to the canagliflozin component, Invokamet-XR is indicated for:
- Cardiovascular Risk Reduction: To reduce the risk of major adverse cardiovascular events (MACE), including heart attack, stroke, or cardiovascular death in adults with Type 2 Diabetes and established cardiovascular disease.
- Diabetic Nephropathy: To reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, and hospitalization for heart failure in adults with Type 2 Diabetes and chronic kidney disease (CKD) with albuminuria.
Primary Endocrinology Indications
- Significant reduction of HbA1c in patients failing on metformin monotherapy.
- Weight management for overweight or obese diabetic patients.
- Stabilization of the Hypothalamic-Pituitary-Adrenal (HPA) Axis by reducing the chronic systemic inflammation and oxidative stress caused by glucose fluctuations.
Dosage and Administration Protocols
Dosing must be individualized based on the patient’s current treatment regimen and renal function.
| Feature | Clinical Specification |
| Standard Frequency | Once daily (QD) |
| Timing | With the evening meal (to maximize absorption and minimize GI upset) |
| Tablet Integrity | Must be swallowed whole. Never crush, chew, or break. |
| Max Daily Dose | 300 mg Canagliflozin / 2000 mg Metformin |
Export to Sheets
Specialized Protocols
- Renal Adjustment: Usage is strictly monitored by the Estimated Glomerular Filtration Rate (eGFR). Initiation is not recommended in patients with an eGFR <45 mL/min/1.73 m2, and the drug is contraindicated if eGFR falls below 30 mL/min/1.73 m2.
- Hydration: Due to the osmotic diuretic effect of SGLT2 inhibitors, patients must be instructed to maintain consistent fluid intake to prevent volume depletion.
- Transitioning: When switching from immediate-release metformin to Invokamet-XR, the dose should be transitioned to the same total daily dose of metformin.
Clinical Efficacy and Research Results
Extensive data from the CANVAS and CREDENCE trials provide robust evidence for the efficacy of this combination.
Numerical Data and Results
- HbA1c Reduction: Research results show a mean reduction of 0.9% to 1.4% when used at maximum doses.
- Weight Loss: Clinical data highlights an average weight loss of 2.8 to 3.9 kg over 26 weeks of therapy.
- Blood Pressure: Numerical data confirms a modest but consistent reduction in systolic blood pressure (approx. 3–5 mmHg) due to mild diuresis and sodium excretion.
- Renal Protection: In the CREDENCE trial (follow-up data through 2025), canagliflozin-based therapy showed a 30% reduction in the risk of progression to end-stage renal disease compared to placebo.
Safety Profile and Side Effects
The extended-release formulation improves GI tolerance, but the inherent risks of both drug classes remain.
Common Side Effects (>10%)
- Genital Mycotic Infections: Yeast infections (vulvovaginal candidiasis or balanitis) due to increased glucose in the urine.
- Urinary Tract Infections (UTIs): Increased risk of bacterial growth in the urinary tract.
- Gastrointestinal Effects: Though reduced in the XR version, mild nausea or diarrhea may still occur.
Serious Adverse Events
- Lactic Acidosis: A rare but fatal complication of metformin, primarily in those with renal or hepatic failure.
- Ketoacidosis: SGLT2 inhibitors can cause “Euglycemic Ketoacidosis,” where ketoacidosis occurs despite near-normal blood sugar levels.
- Volume Depletion: Symptomatic hypotension, particularly in elderly patients or those on diuretics.
- Necrotizing Fasciitis (Fournier’s Gangrene): A rare but severe infection of the perineum.
Research Areas (2024–2026)
Direct Clinical Connections
Active research in 2026 is investigating the role of Invokamet-XR in the management of Heart Failure with Preserved Ejection Fraction (HFpEF). SGLT2 inhibitors appear to improve myocardial energetics regardless of diabetic status.
Generalization and Advancements
The field is moving toward advancements in Multi-Organ Metabolic Health, specifically focusing on the reduction of Non-Alcoholic Steatohepatitis (NASH). Furthermore, research into the HPA Axis is evaluating how the reduction in glucose-induced oxidative stress with SGLT2/Metformin combos might preserve long-term vascular endothelial function.
Disclaimer: This information should be considered exploratory unless supported by definitive clinical evidence. While it represents significant frontiers in medical research, it is not yet applicable to all clinical scenarios or standard of care protocols.
Patient Management and Clinical Protocols
Monitoring and Precautions
- Vigilance: Patients should have an annual foot exam and be educated on proper foot hygiene.
- Laboratory Monitoring: Check eGFR, serum electrolytes, and Vitamin B12 levels (metformin can cause B12 malabsorption) annually.
- “Sick Day” Rules: Invokamet-XR should be temporarily discontinued during periods of severe illness, prolonged fasting, or major surgery (stop 3 days prior) to avoid the risk of ketoacidosis or lactic acidosis.
Do’s and Don’ts
- DO take the medication with your largest meal of the day.
- DO stay hydrated and report any flank pain or burning during urination.
- DON’T consume excessive alcohol, which significantly increases lactic acidosis risk.
- DON’T crush the tablets, as this destroys the extended-release mechanism and increases side effect risks.
Legal Disclaimer
This document is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Invokamet-XR should only be used under the guidance of a licensed healthcare professional, particularly due to the strict requirements for renal monitoring and acid-base balance.
